Advances in mesenchymal stem cell-based therapies for recurrent spontaneous abortion.

Young women's physical and mental health is seriously impacted by recurrent spontaneous abortion (RSA), a prevalent obstetric complication that is becoming more commonplace worldwide. Therefore, a thorough investigation into the pathophysiology of RSA and the development of novel therapeutic strategies are imperative. Recent developments suggest that mesenchymal stem cell (MSC)-based therapies may be viable for addressing RSA. Through a variety of mechanisms, the immunological circumstances at the maternal-fetal contact can be altered, including regulating immune cell homeostasis, enhancing immune tolerance, alleviating inflammatory responses, promoting angiogenic processes, and promoting tissue regeneration. MSCs exhibit a remarkable capacity for multi-differentiation that could enhance pregnancy outcomes. This article provides compelling studies supporting the efficacy of MSC-based therapies in improving pregnancy outcomes in women with RSA.